Oxygen Self-Generating Nanoreactor Mediated Ferroptosis Activation and Immunotherapy in Triple-Negative Breast Cancer

被引:70
|
作者
Li, Ke
Xu, Kun [1 ]
He, Ye [2 ]
Yang, Yulu [1 ]
Tan, Meijun [1 ]
Mao, Yulan [1 ]
Zou, Yanan [1 ]
Feng, Qian [1 ]
Luo, Zhong [3 ]
Cai, Kaiyong [1 ]
机构
[1] Chongqing Univ, Minist Educ, Key Lab Biorheol Sci & Technol, Coll Bioengn, Chongqing 400044, Peoples R China
[2] Duke Univ, Thomas Lord Dept Mech Engn & Mat Sci, Durham, NC 27708 USA
[3] Chongqing Univ, Sch Life Sci, Chongqing 400044, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
self-supplying nanoreactor; ferroptosis; immunotherapy; O2; production; GSH depletion; triple-negative breast cancer; CELL-DEATH; THERAPY; HYPOXIA; NANOPARTICLES; HIF-1-ALPHA; RESISTANCE;
D O I
10.1021/acsnano.2c10893
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The hypoxia microenvironment of solid tumors poses a technological bottleneck for ferroptosis and immunotherapy in clinical oncology. Nanoreactors based on special physiological signals in tumor cells are able to avoid various tumor tolerance mechanisms by alleviating the intracellular hypoxia environment. Herein we reported a nanoreactor Cu2-xSe that enabled the conversion of Cu elements between Cu+ and Cu2+ for the generation of O2 and the consumption of intracellular GSH content. Furthermore, to enhance the catalytic and ferroptosis-inducing activities of the nanoreactors, the ferroptosis agonist Erastin was loaded on the ZIF-8 coating on the surface of Cu2-xSe to up-regulate the expression of NOX4 protein, increase the intracellular H2O2 content, catalyze the Cu+ to produce O2 and activate ferroptosis. In addition, the nanoreactors were simultaneously surface functionalized with PEG polymer and folic acid molecules, which ensured the in vivo blood circulation and tumor-specific uptake. In vitro and in vivo experiments demonstrated that the functionalized self-supplying nanoreactors can amplify the ability to generate O2 and consume intracellular GSH via the interconversion of Cu elements Cu+ and Cu2+, and impair the GPX4/GSH pathway and HIF-1 alpha protein expression. At the same time, by alleviating the intracellular hypoxia environment, the expression of miR301, a gene in the secreted exosomes was decreased, which ultimately affected the phenotype polarization of TAMs and increased the content of IFN gamma secreted by CD8+ T cells, which further promoted the ferroptosis induced by Erastin-loaded nanoreactors. This combined therapeutic strategy of activating the tumor immune response and ferroptosis via self-supplying nanoreactors provides a potential strategy for clinical application.
引用
收藏
页码:4667 / 4687
页数:21
相关论文
共 50 条
  • [11] Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles
    Zhang, Jiaxin
    Zhou, Kaicheng
    Lin, Jingbo
    Yao, Xianxian
    Ju, Dianwen
    Zeng, Xian
    Pang, Zhiqing
    Yang, Wuli
    BIOMATERIALS, 2023, 303
  • [12] Research Progress on Ferroptosis and Nanotechnology-Based Treatment in Triple-Negative Breast Cancer
    Zhang, Jun
    Zhang, Shengjun
    Liu, Minli
    Yang, Zhe
    Huang, Rong
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 347 - 358
  • [13] Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
    Wesolowski, Jakub
    Tankiewicz-Kwedlo, Anna
    Pawlak, Dariusz
    CANCERS, 2022, 14 (16)
  • [14] Immunotherapy in Triple-Negative Breast Cancer: Present and Future
    Kim, Isaac
    Sanchez, Katherine
    McArthur, Heather L.
    Page, David
    CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 259 - 271
  • [15] Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer
    Elizabeth, Melendez Solano
    Cristina, Stevens Barron Jazmin
    Christian, Chapa Gonzalez
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (04) : 431 - 439
  • [16] The clinical promise of immunotherapy in triple-negative breast cancer
    Vikas, Praveen
    Borcherding, Nicholas
    Zhang, Weizhou
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6823 - 6833
  • [17] Clinical trials of immunotherapy in triple-negative breast cancer
    Frederick M. Howard
    Alexander T. Pearson
    Rita Nanda
    Breast Cancer Research and Treatment, 2022, 195 : 1 - 15
  • [18] Clinical trials of immunotherapy in triple-negative breast cancer
    Howard, Frederick M.
    Pearson, Alexander T.
    Nanda, Rita
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (01) : 1 - 15
  • [19] Simvastatin induced ferroptosis for triple-negative breast cancer therapy
    Xianxian Yao
    Ruihong Xie
    Yongbin Cao
    Jing Tang
    Yongzhi Men
    Haibao Peng
    Wuli Yang
    Journal of Nanobiotechnology, 19
  • [20] Ferroptosis: the emerging player in remodeling triple-negative breast cancer
    Li, Jie
    He, Dejiao
    Li, Sicheng
    Xiao, Jun
    Zhu, Zhanyong
    FRONTIERS IN IMMUNOLOGY, 2023, 14